Product
Norditropin®
Name
Norditropin
INN Name
somatropin
FDA Approved
Yes
3 clinical trials
2 organizations
6 indications
1 document
Indication
Growth Hormone DeficiencyIndication
small for gestational age (SGA)Indication
Turner syndromeIndication
Noonan syndromeIndication
ISSClinical trial
A Dose-finding Trial Evaluating the Effect and Safety of Once-weekly Treatment of Somapacitan Compared to Daily Norditropin® in Children With Short Stature Born Small for Gestational Age With no Catch-up Growth by 2 Years of Age or OlderStatus: Active (not recruiting), Estimated PCD: 2021-05-05
Clinical trial
A Multi-center, Randomized, Positive-control, Phase 2&3 Combined Study of Y-shape Pegylated Somatropin in Prepubertal Children With Growth Hormone Deficiency.Status: Completed, Estimated PCD: 2023-06-07
Clinical trial
A Study Comparing the Effect and Safety of Once Weekly Dosing of Somapacitan With Daily Norditropin® as Well as Evaluating Long-term Safety of Somapacitan in a Basket Study Design in Children With Short Stature Either Born Small for Gestational Age or With Turner Syndrome, Noonan Syndrome, or Idiopathic Short StatureStatus: Recruiting, Estimated PCD: 2024-05-20
Document
DailyMed Label: NorditropinOrganization
Physicians Total Care, Inc.Organization
Novo Nordisk